These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 18556775)
1. Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer. Jiang Y; Casey G; Lavery IC; Zhang Y; Talantov D; Martin-McGreevy M; Skacel M; Manilich E; Mazumder A; Atkins D; Delaney CP; Wang Y J Mol Diagn; 2008 Jul; 10(4):346-54. PubMed ID: 18556775 [TBL] [Abstract][Full Text] [Related]
2. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis. Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208 [TBL] [Abstract][Full Text] [Related]
3. Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients. Reimers MS; Kuppen PJ; Lee M; Lopatin M; Tezcan H; Putter H; Clark-Langone K; Liefers GJ; Shak S; van de Velde CJ J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25261968 [TBL] [Abstract][Full Text] [Related]
4. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. Gray RG; Quirke P; Handley K; Lopatin M; Magill L; Baehner FL; Beaumont C; Clark-Langone KM; Yoshizawa CN; Lee M; Watson D; Shak S; Kerr DJ J Clin Oncol; 2011 Dec; 29(35):4611-9. PubMed ID: 22067390 [TBL] [Abstract][Full Text] [Related]
5. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. Kennedy RD; Bylesjo M; Kerr P; Davison T; Black JM; Kay EW; Holt RJ; Proutski V; Ahdesmaki M; Farztdinov V; Goffard N; Hey P; McDyer F; Mulligan K; Mussen J; O'Brien E; Oliver G; Walker SM; Mulligan JM; Wilson C; Winter A; O'Donoghue D; Mulcahy H; O'Sullivan J; Sheahan K; Hyland J; Dhir R; Bathe OF; Winqvist O; Manne U; Shanmugam C; Ramaswamy S; Leon EJ; Smith WI; McDermott U; Wilson RH; Longley D; Marshall J; Cummins R; Sargent DJ; Johnston PG; Harkin DP J Clin Oncol; 2011 Dec; 29(35):4620-6. PubMed ID: 22067406 [TBL] [Abstract][Full Text] [Related]
6. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer. Weissmann-Brenner A; Kushnir M; Lithwick Yanai G; Aharonov R; Gibori H; Purim O; Kundel Y; Morgenstern S; Halperin M; Niv Y; Brenner B Int J Oncol; 2012 Jun; 40(6):2097-103. PubMed ID: 22426940 [TBL] [Abstract][Full Text] [Related]
7. Independent validation of a prognostic genomic signature (ColoPrint) for patients with stage II colon cancer. Maak M; Simon I; Nitsche U; Roepman P; Snel M; Glas AM; Schuster T; Keller G; Zeestraten E; Goossens I; Janssen KP; Friess H; Rosenberg R Ann Surg; 2013 Jun; 257(6):1053-8. PubMed ID: 23295318 [TBL] [Abstract][Full Text] [Related]
8. Hypoxia-driven gene expression is an independent prognostic factor in stage II and III colon cancer patients. Dekervel J; Hompes D; van Malenstein H; Popovic D; Sagaert X; De Moor B; Van Cutsem E; D'Hoore A; Verslype C; van Pelt J Clin Cancer Res; 2014 Apr; 20(8):2159-68. PubMed ID: 24486594 [TBL] [Abstract][Full Text] [Related]
9. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy. Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407 [TBL] [Abstract][Full Text] [Related]
10. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. Clark-Langone KM; Sangli C; Krishnakumar J; Watson D BMC Cancer; 2010 Dec; 10():691. PubMed ID: 21176237 [TBL] [Abstract][Full Text] [Related]
11. Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients. Stotz M; Herzog SA; Pichler M; Smolle M; Riedl J; Rossmann C; Bezan A; Stöger H; Renner W; Berghold A; Gerger A Anticancer Res; 2017 Apr; 37(4):2011-2018. PubMed ID: 28373475 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. Gill S; Haince JF; Shi Q; Pavey ES; Beaudry G; Sargent DJ; Fradet Y Clin Colorectal Cancer; 2015 Jun; 14(2):99-105. PubMed ID: 25619805 [TBL] [Abstract][Full Text] [Related]
13. Confirmation of a metastasis-specific microRNA signature in primary colon cancer. Coebergh van den Braak RRJ; Sieuwerts AM; Lalmahomed ZS; Smid M; Wilting SM; Bril SI; Xiang S; van der Vlugt-Daane M; de Weerd V; van Galen A; Biermann K; van Krieken JHJM; Kloosterman WP; Foekens JA; ; Martens JWM; IJzermans JNM Sci Rep; 2018 Mar; 8(1):5242. PubMed ID: 29588449 [TBL] [Abstract][Full Text] [Related]
14. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. Venook AP; Niedzwiecki D; Lopatin M; Ye X; Lee M; Friedman PN; Frankel W; Clark-Langone K; Millward C; Shak S; Goldberg RM; Mahmoud NN; Warren RS; Schilsky RL; Bertagnolli MM J Clin Oncol; 2013 May; 31(14):1775-81. PubMed ID: 23530100 [TBL] [Abstract][Full Text] [Related]
15. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer. Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775 [TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer. Mo S; Dai W; Xiang W; Li Y; Feng Y; Zhang L; Li Q; Cai G Carcinogenesis; 2019 Jul; 40(7):861-870. PubMed ID: 30933267 [TBL] [Abstract][Full Text] [Related]
17. A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Liu N; Cui RX; Sun Y; Guo R; Mao YP; Tang LL; Jiang W; Liu X; Cheng YK; He QM; Cho WC; Liu LZ; Li L; Ma J Int J Cancer; 2014 Mar; 134(6):1359-68. PubMed ID: 23999999 [TBL] [Abstract][Full Text] [Related]
18. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer. Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841 [No Abstract] [Full Text] [Related]
19. 12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. Yamanaka T; Oki E; Yamazaki K; Yamaguchi K; Muro K; Uetake H; Sato T; Nishina T; Ikeda M; Kato T; Kanazawa A; Kusumoto T; Chao C; Lopatin M; Krishnakumar J; Bailey H; Akagi K; Ochiai A; Ohtsu A; Ohashi Y; Yoshino T J Clin Oncol; 2016 Aug; 34(24):2906-13. PubMed ID: 27325854 [TBL] [Abstract][Full Text] [Related]
20. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Li D; Yan D; Tang H; Zhou C; Fan J; Li S; Wang X; Xia J; Huang F; Qiu G; Peng Z Ann Surg Oncol; 2009 Dec; 16(12):3499-506. PubMed ID: 19672661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]